Indian Army Drug Procurement Tender 2026 for Medicinal Injectables and Tablets in India with CDSCO License, NABL Batch Certificates and DPCO Compliance

Tender Overview

The Indian Army, Department Of Military Affairs, is seeking procurement of medicinal products including tablets and injectables across 10 items, with details largely undisclosed. The request emphasizes regulatory compliance, manufacturer authorization, and quality assurance through NABL batch certificates. The scope covers products such as Amantadine, Pramipexole, Fentanyl injections, Vecuronium, Atracurium, and related formulations. Key differentiators include mandatory CDSCO/DCGI drug licenses, DPCO ceiling price disclosure, and a compliance sheet listing MRP, GST, and manufacturing company. The tender stipulates supplier flexibility for unit-level quantities via an option clause, and requires OEM authentication. Location and total estimated value are not disclosed in the available data.

Technical Specifications & Requirements

• 10 drug/medical item BOQ with absence of explicit quantity data
• Option Clause: +/- 25% quantity at contract, extended delivery time formula with minimum 30 days
• Authorization: Manufacturer/OEM authorization form required
• Compliance Sheet: includes Nomenclature, MRP, GST%, MFG Company
• Regulatory licenses: Copy of valid CDSCO/DCGI drug license to be submitted
• Quality/QA: Batch test certificate from Govt authorized lab/NABL required for supply; non-compliance leads to ban
• Price control: DPCO ceiling price to be attached with bid
• Documentation: Notarized undertaking; bid details include MRP, GST, and MFG
• Deliverables require adherence to drug procurement standards and traceability
• 10-item scope with distributed quantities, lacking explicit unit data

Terms & Eligibility

• Option clause enabling 25% quantity increase/decrease at contract at contracted rates
• OEM authorization mandatory for distributors/agents
• Compliance Sheet and batch test certificates mandatory
• Notarized undertaking and DPCO ceiling price attachment required
• CDSCO/DCGI drug license copy required
• Bidders must meet regulatory and QA requirements to avoid bid rejection
• No explicit EMD amount provided in the data; verify in tender portal
• Delivery schedule aligned with extended delivery periods as per option clause